HURA7:45 AMTuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technologytuhurabio.com
HURA7:45 AMTuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancerstuhurabio.com
HURA7:45 AMTuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conferencetuhurabio.com
HURA7:45 AMTuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Updatetuhurabio.com
HURA7:40 AMTuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conferencetuhurabio.com